Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LIPE | Q05469 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6903141 | 0.81 | KDM4E (0.42) | KDM4EGAAHPGDHRH3ALDH1A1 | |
| SCHEMBL681878 | 0.81 | KDM4E (0.42) | KDM4EGAAHPGDHRH3ALDH1A1 | |
| SCHEMBL89043 | 0.81 | KDM4E (0.42) | KDM4EGAAHPGDHRH3ALDH1A1 | |
| SCHEMBL16285870 | 0.79 | KDM4E (0.41) | KDM4EGAAHPGDHRH3ALDH1A1 | |
| SCHEMBL1117927 | 0.79 | KDM4E (0.41) | KDM4EGAAHPGDHRH3ALDH1A1 | |
| SCHEMBL21363734 | 0.79 | KDM4E (0.41) | KDM4EGAAHPGDHRH3ALDH1A1 | |
| SCHEMBL19750189 | 0.79 | KDM4E (0.41) | KDM4EGAAHPGDHRH3ALDH1A1 | |
| SCHEMBL21398619 | 0.79 | KDM4E (0.41) | KDM4EGAAHPGDHRH3ALDH1A1 | |
| SCHEMBL24918704 | 0.77 | KDM4E (0.40) | KDM4EGAAHPGDHRH3ALDH1A1 | |
| SCHEMBL7154832 | 0.77 | KDM4E (0.44) | KDM4EGAAHPGDHRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5668165-A | TREATMENT OF HIV INFECTIONS | SCRIPTGEN PHARMACEUTICALS, INC. (US) | 1997-09-16 | — | — | US | claimed |
| EP-2139472-B1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-8288432-B2 | Tetrahydroindole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20100120749-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-05-13 | — | — | US | disclosed |
| EP-2139472-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-01-06 | — | — | EP | disclosed |
| EP-2000176-A1 | Tetrahydroindole derivatives as NADPH Oxidase inhibitors | GenKyo Tex (CH) | 2008-12-10 | — | — | EP | disclosed |
| WO-2008116926-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120749-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | CYBB, NQO1, NOX4 | KDM4E 3163/4885GAA 654/4885HPGD 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.